UroGen Pharma Ltd (URGN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

URGN UroGen Pharma Ltd

Watchlist

9.360
-0.150-1.58%

Close Feb 26 16:00 ET

9.580
+0.220+2.35%

Post 20:01 ET

394.99MMarket Cap-3.10P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now?
Yahoo FinanceFeb 25 12:30 ET
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $64
Moomoo NewsFeb 25 07:33 ET · Ratings
UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference
UroGen PharmaFeb 24 00:00 ET
Express News | As Consideration For Assets, UroGen Issued IconOVir 374,843 Of Its Ordinary Shares, Agreed To One-Time Payment Of $15M Upon Milestones And A Low Single-Digit Royalty Percentage
BenzingaFeb 20 08:04 ET
Express News | UroGen Acquires Assets Relating To ICVB-1042 From IconOVir
BenzingaFeb 20 08:03 ET
UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations
UroGen PharmaFeb 20 00:00 ET

Comments

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations

$UroGen Pharma Ltd (URGN.US)$
UroGen's Major Pipeline Play: Revolutionary Cancer-Fighting Virus Acquisition Reshapes Growth Strategy

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations

$UroGen Pharma Ltd (URGN.US)$

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

$UroGen Pharma Ltd (URGN.US)$
Breakthrough Bladder Cancer Treatment Achieves 83% Response Rate, FDA Decision Coming 2025

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

2

1

Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal o

$UroGen Pharma Ltd (URGN.US)$
Clinical Trial Results: Cancer Drug Maintains Response for Nearly 4 Years, Surpassing Expectations

Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal o

Oct 15, 2024 15:37

$UroGen Pharma Ltd (URGN.US)$

Read more

Trending Stocks

Symbol Mini Chart % Chg

Unlock the Full List